Lebanon

Lebanon

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.82 (2.43 - 3.24) 2019 Modelled IHME
3 (2.60 - 3.40) 2018 Modelled IHME
3.07 (2.64 - 3.52) 2017 Modelled IHME
3.06 (2.63 - 3.51) 2016 Modelled IHME
3.05 (2.59 - 3.51) 2015 Modelled IHME
3.06 (2.61 - 3.51) 2014 Modelled IHME
3.11 (2.64 - 3.56) 2013 Modelled IHME
3.18 (2.68 - 3.65) 2012 Modelled IHME
3.26 (2.71 - 3.74) 2011 Modelled IHME
3.33 (2.72 - 3.84) 2010 Modelled IHME
3.4 (2.82 - 3.91) 2009 Modelled IHME
3.49 (2.90 - 4.02) 2008 Modelled IHME
3.57 (3 - 4.11) 2007 Modelled IHME
3.66 (3.08 - 4.24) 2006 Modelled IHME
3.73 (3.15 - 4.37) 2005 Modelled IHME
3.78 (3.21 - 4.44) 2004 Modelled IHME
3.83 (3.26 - 4.50) 2003 Modelled IHME
3.88 (3.30 - 4.57) 2002 Modelled IHME
3.93 (3.32 - 4.67) 2001 Modelled IHME
3.98 (3.35 - 4.77) 2000 Modelled IHME
4.04 (3.40 - 4.82) 1999 Modelled IHME
4.11 (3.45 - 4.91) 1998 Modelled IHME
4.18 (3.46 - 4.98) 1997 Modelled IHME
4.25 (3.46 - 5.03) 1996 Modelled IHME
4.29 (3.48 - 5.07) 1995 Modelled IHME
4.32 (3.54 - 5.04) 1994 Modelled IHME
4.35 (3.60 - 5.07) 1993 Modelled IHME
4.37 (3.66 - 5.08) 1992 Modelled IHME
4.39 (3.70 - 5.09) 1991 Modelled IHME
4.4 (3.73 - 5.10) 1990 Modelled IHME
1.31 (1.03 - 1.64) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.58 (0.43 - 0.76) 2019 Modelled IHME
0.65 (0.48 - 0.85) 2018 Modelled IHME
0.68 (0.50 - 0.89) 2017 Modelled IHME
0.67 (0.50 - 0.88) 2016 Modelled IHME
0.67 (0.50 - 0.87) 2015 Modelled IHME
0.68 (0.51 - 0.87) 2014 Modelled IHME
0.7 (0.53 - 0.91) 2013 Modelled IHME
0.74 (0.55 - 0.96) 2012 Modelled IHME
0.78 (0.58 - 1.02) 2011 Modelled IHME
0.82 (0.61 - 1.09) 2010 Modelled IHME
0.87 (0.64 - 1.15) 2009 Modelled IHME
0.94 (0.69 - 1.23) 2008 Modelled IHME
1 (0.73 - 1.30) 2007 Modelled IHME
1.06 (0.77 - 1.37) 2006 Modelled IHME
1.08 (0.78 - 1.41) 2005 Modelled IHME
1.07 (0.78 - 1.39) 2004 Modelled IHME
1.05 (0.76 - 1.37) 2003 Modelled IHME
1.03 (0.75 - 1.35) 2002 Modelled IHME
1.01 (0.74 - 1.34) 2001 Modelled IHME
1 (0.74 - 1.34) 2000 Modelled IHME
1.19 (0.87 - 1.58) 1999 Modelled IHME
1.65 (1.21 - 2.14) 1998 Modelled IHME
2.2 (1.59 - 2.86) 1997 Modelled IHME
2.67 (1.92 - 3.50) 1996 Modelled IHME
2.89 (2.08 - 3.79) 1995 Modelled IHME
2.92 (2.14 - 3.78) 1994 Modelled IHME
2.94 (2.19 - 3.80) 1993 Modelled IHME
2.96 (2.22 - 3.81) 1992 Modelled IHME
2.97 (2.21 - 3.81) 1991 Modelled IHME
2.98 (2.22 - 3.85) 1990 Modelled IHME
0.21 (0.14 - 0.30) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
49 (40 - 58) 2019 Modelled IHME
49 (40 - 58) 2018 Modelled IHME
49 (40 - 59) 2017 Modelled IHME
49 (40 - 59) 2016 Modelled IHME
49 (40 - 59) 2015 Modelled IHME
49 (40 - 59) 2014 Modelled IHME
49 (40 - 59) 2013 Modelled IHME
49 (40 - 59) 2012 Modelled IHME
49 (40 - 58) 2011 Modelled IHME
49 (40 - 59) 2010 Modelled IHME
49 (40 - 59) 2009 Modelled IHME
50 (41 - 60) 2008 Modelled IHME
50 (41 - 60) 2007 Modelled IHME
51 (42 - 60) 2006 Modelled IHME
51 (42 - 60) 2005 Modelled IHME
51 (42 - 60) 2004 Modelled IHME
51 (41 - 60) 2003 Modelled IHME
51 (41 - 60) 2002 Modelled IHME
51 (41 - 61) 2001 Modelled IHME
51 (41 - 61) 2000 Modelled IHME
51 (42 - 61) 1999 Modelled IHME
52 (42 - 61) 1998 Modelled IHME
52 (43 - 62) 1997 Modelled IHME
52 (43 - 62) 1996 Modelled IHME
52 (43 - 62) 1995 Modelled IHME
53 (43 - 62) 1994 Modelled IHME
53 (44 - 62) 1993 Modelled IHME
53 (44 - 62) 1992 Modelled IHME
53 (44 - 62) 1991 Modelled IHME
53 (44 - 62) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
80 2018 Survey/reported WHO/UNICEF
80 2017 Survey/reported WHO/UNICEF
80 2016 Survey/reported WHO/UNICEF
80 2015 Survey/reported WHO/UNICEF
80 2014 Survey/reported WHO/UNICEF
80 2013 Survey/reported WHO/UNICEF
83 2012 Survey/reported WHO/UNICEF
86 2011 Survey/reported WHO/UNICEF
88 2010 Survey/reported WHO/UNICEF
91 2009 Survey/reported WHO/UNICEF
94 2008 Survey/reported WHO/UNICEF
94 2007 Survey/reported WHO/UNICEF
94 2006 Survey/reported WHO/UNICEF
94 2005 Survey/reported WHO/UNICEF
94 2004 Survey/reported WHO/UNICEF
94 2003 Survey/reported WHO/UNICEF
94 2002 Survey/reported WHO/UNICEF
90 2001 Survey/reported WHO/UNICEF
90 2000 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
80 2018 Survey/reported WHO/UNICEF
80 2017 Survey/reported WHO/UNICEF
80 2016 Survey/reported WHO/UNICEF
80 2015 Survey/reported WHO/UNICEF
80 2014 Survey/reported WHO/UNICEF
80 2013 Survey/reported WHO/UNICEF
80 2012 Survey/reported WHO/UNICEF
80 2011 Survey/reported WHO/UNICEF
81 2010 Survey/reported WHO/UNICEF
81 2009 Survey/reported WHO/UNICEF
81 2008 Survey/reported WHO/UNICEF
80 2007 Survey/reported WHO/UNICEF
78 2006 Survey/reported WHO/UNICEF
77 2005 Survey/reported WHO/UNICEF
75 2004 Survey/reported WHO/UNICEF
74 2003 Survey/reported WHO/UNICEF
77 2002 Survey/reported WHO/UNICEF
80 2001 Survey/reported WHO/UNICEF
83 2000 Survey/reported WHO/UNICEF
86 1999 Survey/reported WHO/UNICEF
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.02 (0.84 - 1.26) 2019 Modelled IHME
0.76 (0.62 - 0.92) 2018 Modelled IHME
0.62 (0.51 - 0.76) 2017 Modelled IHME
0.61 (0.50 - 0.73) 2016 Modelled IHME
0.6 (0.50 - 0.73) 2015 Modelled IHME
0.61 (0.50 - 0.73) 2014 Modelled IHME
0.61 (0.50 - 0.73) 2013 Modelled IHME
0.62 (0.51 - 0.74) 2012 Modelled IHME
0.62 (0.51 - 0.75) 2011 Modelled IHME
0.63 (0.52 - 0.76) 2010 Modelled IHME
0.65 (0.54 - 0.78) 2009 Modelled IHME
0.68 (0.56 - 0.82) 2008 Modelled IHME
0.71 (0.59 - 0.86) 2007 Modelled IHME
0.74 (0.61 - 0.89) 2006 Modelled IHME
0.75 (0.61 - 0.91) 2005 Modelled IHME
0.75 (0.61 - 0.91) 2004 Modelled IHME
0.73 (0.60 - 0.89) 2003 Modelled IHME
0.72 (0.59 - 0.88) 2002 Modelled IHME
0.71 (0.58 - 0.86) 2001 Modelled IHME
0.71 (0.58 - 0.86) 2000 Modelled IHME
0.71 (0.58 - 0.86) 1999 Modelled IHME
0.71 (0.59 - 0.86) 1998 Modelled IHME
0.72 (0.60 - 0.87) 1997 Modelled IHME
0.74 (0.60 - 0.89) 1996 Modelled IHME
0.75 (0.61 - 0.90) 1995 Modelled IHME
0.78 (0.63 - 0.93) 1994 Modelled IHME
0.82 (0.68 - 0.98) 1993 Modelled IHME
0.87 (0.72 - 1.05) 1992 Modelled IHME
0.94 (0.77 - 1.13) 1991 Modelled IHME
1.01 (0.82 - 1.24) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

People who inject drugs (PWID)
Download
Value (%) Year Type Source
23.4 (15.30 - 33.30) 2013 Survey/reported Merabi Z et al, 2016

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
23 (16 - 32) 2019 Modelled IHME
23 (16 - 31) 2018 Modelled IHME
23 (16 - 31) 2017 Modelled IHME
23 (16 - 31) 2016 Modelled IHME
23 (16 - 31) 2015 Modelled IHME
23 (16 - 31) 2014 Modelled IHME
23 (15 - 31) 2013 Modelled IHME
23 (15 - 31) 2012 Modelled IHME
23 (15 - 32) 2011 Modelled IHME
23 (15 - 32) 2010 Modelled IHME
23 (15 - 32) 2009 Modelled IHME
23 (15 - 31) 2008 Modelled IHME
23 (15 - 31) 2007 Modelled IHME
23 (15 - 31) 2006 Modelled IHME
23 (15 - 31) 2005 Modelled IHME
23 (15 - 31) 2004 Modelled IHME
23 (15 - 31) 2003 Modelled IHME
23 (15 - 32) 2002 Modelled IHME
23 (15 - 31) 2001 Modelled IHME
23 (15 - 31) 2000 Modelled IHME
22 (15 - 31) 1999 Modelled IHME
22 (15 - 31) 1998 Modelled IHME
22 (14 - 30) 1997 Modelled IHME
22 (15 - 30) 1996 Modelled IHME
22 (14 - 30) 1995 Modelled IHME
22 (14 - 30) 1994 Modelled IHME
21 (14 - 29) 1993 Modelled IHME
21 (14 - 29) 1992 Modelled IHME
21 (14 - 29) 1991 Modelled IHME
21 (14 - 29) 1990 Modelled IHME
Showing out of
Show more
Technical notes
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
2.82 (%)
2019
(2.43 - 3.24(%))
IHME
HCV (RNA/cAg+)
1.02 (%)
2019
(0.84 - 1.26(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
312
2019
(219 - 470)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
284
2019
(171 - 432)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.58 (%)
2019, latest modelled
(0.43 - 0.76(%))
IHME

Prevalence PWID

HCV
23.40 (%)
2013, survey/surveillance
(15.30 - 33.30(%))
Merabi Z et al, 2016

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
80 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines